AllianceXPartners

AllianceXPartners is officially open for business. We exist to solve a specific, recurring problem: US biotechs holding a late-stage drug candidate that missed its overall Phase 3 endpoint but showed a real, FDA-recognized effect in a defined sub-population — and have no cash left to fund the confirmatory trial that could get it approved.

Our model sources an EAEU pharmaceutical partner willing to fund that trial in exchange for exclusive regional rights, routes the trial through the SMOMT clinical network across a compliant two-track site footprint, and structures a single protocol that supports both EAEU registration and a US FDA sub-population filing. The biotech gets its pivotal trial at no cash cost; AllianceXPartners is paid through a royalty, a warrant, a services margin and an EAEU royalty.

Over the next six months we’re focused on standing up the compliance perimeter, diligencing our initial pipeline, and signing a lighthouse deal with one flagship asset. Read more on The Opportunity and How It Works, or get in touch if you think your program — or your capital — belongs in this pipeline.